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ABSTRACT 
Objective: The mass characterization of five trace level related impurities of Irbesartan was performed through the “nMS2” technique of triple 
quadrupole mass spectrometer and also to Correlated to the impurity origin. 
Methods: A simple & effective patented process was applied to get the impurity profile, and mass characterization was performed through the 
“nMS2” technique of triple quadrupole mass spectrometer analyser. 
Results: The simple production scan in differential collision energies is coined as “nMS2” technique of the triple quadrupole analyzer. The 
molecular ion fragmentation occurs with multiple collision energies and provides meaningful MSMS fragments for characterizing five trace level 
impurities less than 0.5% of angiotensin II receptor antagonist-Irbesartan. The origin of the impurity formation in the synthetic process was 
successfully related to the Spiro ketones. 
Conclusion: The results obtained in this research clearly indicates the approach of “nMS2
Keywords: nMS
” technique was very useful in the identification and 
structural prediction of trace level related impurities of Irbesrtan. 
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Safety and efficacy of pharmaceutical substances are the two 
fundamental issues in drug therapy. The safety of a drug is determined 
by its pharmacological or toxicological profile as well as the adverse 
effects caused by the impurities in bulk and dosage forms. The drug 
should be safe, i.e. it should have an acceptably low risk of adverse effects 
with doses of drug which provide the desired therapeutic effects. The 
impurities in drugs often possess unwanted pharmacological or 
toxicological effects by which any benefit from their administration may 
be outweighed. Thus the quality of the drug is directly related to safety. 
The quality and safety of a drug is generally assured by monitoring it 
using suitable analytical techniques and controlling the Impurities 
effectively. Thus, the analytical activities concerning impurities in drugs 
are among the most important aspect in the modern pharmaceutical 
analysis [1-5]. The International Conference on Harmonization (ICH) 
guidelines defines the impurity as “Any component of the medicinal 
product which is not the chemical entity defined as the active substance 
or an excipient in the product”. The impurity profiling is hence 
considered to be the analytical activities with the aim of detecting, 
identifying or elucidating the structure and quantitatively determining 
impurities in bulk drugs and pharmaceutical formulations [6-10].  
The impurities were broadly classified as related and non-related 
impurities. In pharmaceuticals the manufacturing facilities follows 
stringent manufacturing practices, thus the possibility for the non-
related unknown impurity formation will be very rare considerably 
difficult to identify and characterize this totally unknown impurity. 
Development of a cost-effective process is always desirable for 
sustained commercialization of any drug substances. Therefore, 
continuous innovations are constantly employed by process chemist 
to implement cost-effective synthesis scheme in scale-up operations 
and hence successful commercialization of the drug substances. This 
kind of effort requires the use of commercially available 
conventional raw materials along with plant-based solvents for the 
process, workup and purification of the final product ensuring the 
quality of the product. This report demonstrates how the MSMS 
architecture of LCMS-8040 acts as an “enabler” in identifying 
process-related impurities appropriately to ensure the quality of the 
drug substance Irbesartan. Irbesartan is the angiotensin II receptor 
antagonists intended for the treatment of hypertension and also for 
the delay progression of diabetic nephropathy. It is often formulated 
with a lesser dosage level of thiazide diuretic The salient features of 
LCMS 8040 like Synchronized Survey Scan (SSS) provides the MS 
and MSMS data simultaneously in a single run and paves the way for 
rapid identification of impurities. Further, the simultaneous MS 
analysis in both positive and negative modes, MSMS analysis with 
different collision energies and MSMS analysis with neutral loss 
function have enabled us to characterize the impurities of 
Irbesartan. 
MATERIALS AND METHODS 
Chemicals and reagents 
The synthetic chemicals are LR grade for step 1 and step2 of 
synthetic reaction scheme. AR grade reagents are used for step3. 
Cyano methyl biphenyl and spiroketone is procured from 
LobaChemi along with scheme reagents. Analytical grade reagents 
and LCMS grade solvents is used for the LCMS and LCMSMS analysis. 
Instrumentation 
An UFMS consisting of the Shimadzu UHPLC NEXERA as a frontend 
for the Shimadzu LCMS 8040 triple quadrupole mass spectrometer. 
A reverse phase Shimadzu shimpak XR-ODS (50 X3.0 mm, 2.2μm) 
column was used for the chromatographic separation. The 
chromatographic data is recorded with Shimadzu Lab solution 
software. The LCMS and LCMSMS were performed with the FCV12 
divert valve arrangement. ESI was used as the ionization source for 
the mass analysis in both positive and negative polarity. 
Chromatographic and mass spectrometric conditions  
The UHPLC separation was carried out with Shimadzu shimpak XR-
ODS (50 X3.0 mm, 2.2μm) column using 0.1% fomic acid in water at 
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3.4 pH and acetonitrile as mobile phase in a gradient mode. The 
time/%B concentration of the gradient programme is 0.01/33, 
2.00/33, 10.00/60, 13.00/60,15.00/33,17.00/33. The flow rate was 
0.3 ml/min, and the injection volume is 10μL. LC-MS/MS was carried 
out with Electrospray ionization (ESI) in positive and negative mode 
of detection. Nitrogen was used as a nebulizer gas. Collision-induced 
dissociation was achieved by argon as collision gas. The operating 
conditions for MS scan were: DL temperature 250 °C; nebulizer gas, 
3.0L/min; dry gas, 15.0L/min; ESI voltage 4.5kV; heat block, 350 °C 
and the sacn range, 150 to 2000amu. The selected quazi molecular 
ion was subjected to the LCMSMS analysis in 11 different collision 
energies (CE=5v to 60v in increment of 5). 
DISCUSSION 
Irbesartan was in-house synthesized at Indian Institute of 
chromatography and Mass Spectrometry (IICMS), Chennai, India for 
academic research. A three-stage synthetic root is adapted as per 
EP1918288A1 [11]. The synthetic scheme is shown in fig. 1.  
The step 1(S-1) corresponds to alkyl bromination followed by 
spiroketone substitution in step2 (S-2) and cyclization with a 
reduction to form tetrazole ring in step3(S-3). The purity of the 
compound was found to be 99.21% (Area normalization method) 
with five trace level impurities. 
 
Fig. 1: Synthetic scheme for Irbesartan [11] 
   
Though a three-step process is used to synthesize Irbesartan, the 
HPLC analysis shows the presence of five impurities, whose 
concentration varies from 0.04% to 0.32% Area (table 1). Fig. 2 
shows the HPLC chromatogram of Irbesartan and its five trace level 













































Mol. Wt.: 428.53  
Fig. 2: HPLC chromatogram of Irbesartan and its trace level impurities 
Dataf ile Name:LCMS_3103011.lcd
Sample Name:Irbesartan  250 ppm
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Table 1: The Retention time and area percentage of Irbesartan and impurities 
Impurities Retention time (min) Level of impurities in UV detection (%Area) 
Impurity-1 4.05 0.32 
Impurity-2 6.12 0.11 
Impurity-3 6.45 0.26 
Impurity-4 7.09 0.04 
Impurity-5 10.86 0.07 
 
The trace level impurity area is shown in table 1 
The impurity variance is between 0.04%a/a to 0.32%a/a. Thus it is 
less than 0.5%a/a in the analyzed chromatographic conditions [12-
14]. On comparing the polarity in the chromatographic impurity 
elution order, it was observed that four impurities are polar with 
respect to irbesartan and the one with later elution is relatively 
nonpolar to irbesartan. This also infers that the structure of these 
impurities has functional group variances or aliphatic chain 
increments/decrements reflecting to polarity. 
The mass spectrometric analysis in impurity characterization is 
the first approach for the possible clue for the formation of 
impurity in the reaction process of the intended product. The 
Irbesartan and its impurities were mass analyzed. The molecular 
ion of Irbesartan has been observed as m/z 429 [M+1] in ESI 
positive mode, confirmed in the simultaneous ESI negative mode 
analysis as m/z 427 [M-1]. Similar to irbesartan, the molecular 
mass of the impurities was also confirmed by the simultaneous 
positive [M+1] ions and negative [M-1] ions and tabulated in 
table 2. 
 
Table 2: Molecular mass of Irbesartan and impurities 
Name Molecular ion Molecular mass (Da) 
Positive Negative 
Impurity 1 373 371 372 
Impurity 2 415 413 414 
Impurity 3 447 445 446 
Impurity 4 427 425 426 
Impurity 5 443 441 442 
The impurities are correlated to Irbesartan and found all the impurities are behaving similar in mass spectrometry with ionization both in positive 
and negative ionization. 
 
The LCMS/MS-“nMS2
The sanctity of an LCMS analysis remains in the novel approach of its 
intended application. The stringent specification of international 
regulatory bodies has made it necessary to characterize the 
impurities in trace level - (0.1%). This is to minimize the adverse 
biological effects of the unknown impurities and also to improve the 
potency of the active component. Characterization of a compound 
and its trace level impurities requires MS and MSMS analysis. The 
segmental analysis was performed to obtain the above molecular 
masses for irbesartan. The MSMS analysis of irbesartan with 
nine different collision energies simultaneously in ESI positive 
ionization shows the characteristic fragmentation ions such as 
m/z 429, m/z 207, m/z 195, m/z 180 and m/z 84 of irbeartanis 
shown in table 3 and the proposed fragmentation pathway is 




Fig. 3: The proposed fragmentation pathway of Irbesartan 
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Table 3: Compiled mass fragments of Irbesartan 
CE Irbesartan 
-5 429         
-10 429 207        
-15 429 207 195       
-20 429 207 195       
-25  207 195       
-30  207 195  180     
-35  207 195 190,192 180   84  
-40  207 195 190,192 180  153 84  
-45  207 195 190,192 180 165,167 153 84  
-50  207 195 190,192 180 165,167 151 84 77 
-60  205  190,192 180 165,167  84 77 
 
The MS identified impurities are subjected to the MSMS analysis 
simultaneously at eleven different collision energies for the five 
impurities in both positive and negative ESI mode. The MSMS 
chromatogram and compiled mass fragments in positive mode is 
shown in fig. 4 and the MSMS chromatogram and compiled mass 






Fig. 4: The overlaid MSMS chromatogram of five impurities evaluated under 11 different collisions (55 data in 15 min) and compiled mass 
fragments in ESI Positive mode 
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Fig.5: The overlaid MSMS chromatogram of five impurities evaluated under 11 different collisions (55 data in 15 min) in ESI Negative 
mode 
 
The positive mode nMS2 compiled fragments have given the 
similarity ion of m/z207 ascertainging the presence of tetrazole 
ring in all the five impurities. The negative mode nMS2
Thus the MSMS spectral analysis both in positive and negative mode 
has ascertained the possible correlations and necessitated variances 
with respect to irbesartan. This “nMS
 compiled 
fragments have given the comparative differentiation 15 units 
leaves the prediction to the possibility of methyl/alkyl group 
variance in the irbesartan impurities. Thus the data analysis has 
enabled us to observe the presence or absence of a methyl group 
leading to the formation of impurity-2 and impurity-5 respectively. 
All the impurities except impurity-3 have their origin from the raw 
material spiroketones used in the synthesis of irbesartan. 
Impurity-3 is already reported as USP impurity-A [7].  
To match the origin of the impurity, the synthetic root is screened 
carefully giving raise to the origin of the impurities are from the step II. 
Based on the MSMS spectral analysis both in positive and negative 
mode, the structure of the process related impurities with the 
molecular weight was shown in the schematic representation in fig. 6. 
2” approach and the data 
correlation is highly important for the structural identification of 
any related impurities. The MSMS correlations provide the better 
understanding of the functional behavior. 
Saravanan et al. 























































Mol. Wt.: 455.57  
Fig. 6: The Schematic representation of Impurity origin in irbesartan 
 
CONCLUSION 
The MSMS approach of the “nMS2” technique was evaluated in detail for 
the structural identification the trace level impurities of Irbesarton. On 
the successful evaluation of the impurities, it was observed that the 
impurities are a methylated, demethylated and alkenylated analogue of 
irbesartan. This approach is very fast and efficient as the mass 
identification is done after chromatographic resolution. The product ion 
formed was predominately from the parental ion thus the ion reliability 
is always higher and more meaningful data for interpretation. The mass 
segmental analysis with “nMS2
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